Latest From Tesaro Inc.
The results of the POLO trial, showing a benefit of Myriad’s BRACAnalysis CDx companion diagnostic for AstraZeneca’s Lynparza (olaparib) to treat pancreatic cancer offer more support for the new guidelines from the National Comprehensive Cancer Network recommending genetic testing for all pancreatic cancer patients. Myriad also stands to benefit from the growing support for genetic testing of breast cancer patients.
A near doubling of progression-free survival in the POLO study of AstraZeneca/Merck & Co’s Lynparza could usher in a new era of targeted therapy for metastatic pancreatic patients with germline BRCA mutations, and open up a third indication for the leading PARP inhibitor.
Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.
Delegates at this year’s ASCO meeting in Chicago will hear late-breaking clinical data for a number of studies from AstraZeneca, Novartis, Pfizer, Astellas, Merck & Co and Seattle Genetics which are set to shake up their respective markets. There will also be more clarity on where Lilly’s Lartruvo went so wrong.
- Specialty Pharmaceuticals
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Tesaro Inc.
- Senior Management
Lonnie Moulder, CEO
Timothy Pearson, EVP, CFO
Mary Lynne Hedley, PhD, Pres. & COO
Grant C Bogle, SVP, Chief Commercial Officer
William Aitchison, PhD, SVP, Technical ops
Allene Diaz, SVP, Global Commercial Development
Joseph Farmer, SVP, General Counsel & Corp Secretary
Martin Huber, MD, SVP, CMO
Jennifer Jackson, PhD, SVP, Global RA and QA
Orlando Oliveira, SVP, International
- Contact Info
Phone: (339) 970-0900
1000 Winter St.
Waltham, MA 02451
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.